Lilly has announced that it plans to submit a Biologics License Application, commonly called a BLA, to the FDA during the first quarter of 2027
Two of the most widely discussed names are Wegovy and Mounjaro
The GLP-1 Bridge reflects that medical consensusand recognizes that new therapies have fundamentally changed whats possible in obesity treatment
I also consider GLP-1s for individuals with visceral fat accumulation, signs of insulin resistance, fatty liver or inflammatory conditions, so even in those who appear lean externally but have internal metabolic or inflammatory imbalances." However, Dr
Plus, it may not work: In a letter to the Fuel for the Sole podcast , one male runner admitted snagging an Ozempic prescription in an effort to lose a few pounds and speed up his pace
Oral supplementation can help fill the gap